Medicare Advantage Open Enrollment: What to Know About Switching Plans

Medicare Advantage enrollees have a special open enrollment window through March 31 during which they may make a single coverage change, including switching plans or moving to original Medicare. The article highlights key trade-offs: lower premiums can be offset by higher deductibles, copays, narrower networks and loss of supplemental benefits, while moving to original Medicare may require Medigap underwriting and can expose beneficiaries to unlimited out-of-pocket liability despite broader provider access. Insurers offering Medicare Advantage and supplemental Medigap products should watch enrollment flows and risk selection during this period, as beneficiary switches could affect utilization patterns and margins for the remainder of the year.

Analysis

Market structure: Short window (now–Mar 31) raises enrollment churn and benefits large, vertically integrated Medicare Advantage (MA) insurers with broad networks and broker distribution (UNH, HUM, CVS) while stressing smaller regional plans and standalone Medigap writers that lack scale. Scale gives pricing power on plan design and provider negotiations; a 1–3% swing in share nationally (~$1–3bn revenue reallocation industrywide annually) is plausible if consumers chase $0‑premium plans. Market cross‑assets: expect modest widening of subordinated insurer credit spreads on uncertainty, a 10–20% lift in near‑term options vol for large insurers into Apr earnings, limited FX/commodities impact.

Risk assessment: Tail risks include a CMS policy shock (risk‑adjustment audit tightening or >3% payment cuts) and adverse state Medigap underwriting rulings that could force MA inflows back to incumbents; these would hit margins over 6–18 months. Immediate (days): enrollment flow headlines; short (weeks–months): Q2 membership and claims mix; long (quarters–years): structural MA penetration (>50% of Medicare) continues to rise, amplifying scale winners. Hidden dependencies: provider network adequacy, broker commission changes, and local plan formularies drive real consumer switching.

Trade implications: Direct: establish 2–3% long positions in UNH and HUM (scale + diversified revenue) ahead of Apr–Jun membership disclosures; trim regional/managed Medicaid names with narrow MA exposure (e.g., OSTK? avoid generic) and keep 1% hedges. Options: buy 3‑6 month call spreads on HUM (buy 1x 6‑month 5%‑OTM call, sell 1x 10%‑OTM) to express upside with defined risk; buy protective 6‑month puts if CMS cuts >3% materialize. Sector rotation: overweight Health Insurers and broker/benefit administrators; underweight small-cap regional insurers and select Medicare Advantage pure‑play REITs exposed to outpatient disruptions.

Contrarian angles: Consensus expects MA churn to hurt incumbent margins; underappreciated is higher churn enabling upsell of supplemental benefits and higher premium take from supplemental products (broker commissions + A/R float) — a 100–200bp margin recovery is possible for best‑in‑class players over 12–24 months. Historical precedent: 2019 CMS scare compressed multiples briefly but stocks regained ground as enrollments rose; if CMS final rule is benign (≤2% change) expect snapback. Watch for unintended consequence: mass migration to original Medicare could spike Medigap demand and premiums, creating a secondary growth vector for reinsurers and life companies writing supplements.

Key Decisions for Investors

• Establish a 2–3% long position in UnitedHealth Group (UNH) within 1–2 weeks to capture scale advantage through Apr–Jun membership changes; set a stop loss at -12% and target +15–25% over 6–12 months.
• Establish a 2% long position in Humana (HUM) and hedge with a 6‑month 5%‑OTM/10%‑OTM call spread (buy 1x 5%‑OTM call, sell 1x 10%‑OTM) to limit premium outlay while retaining upside if MA mix improves; allocate cash equal to ~0.5% portfolio for premium.
• Reduce exposure by 50% to small/regional Medicare Advantage specialists (positions under $2bn market cap) and redeploy into large-cap insurers over the next 30 days as enrollment churn favors distribution scale.
• Buy 6‑month protective puts (1–2% notional) on UNH/HUM if CMS issues a draft rule with payment reductions >3% (monitor CMS final payment notice expected early April); if cut >3% execute puts, otherwise allow options to expire.
• Monitor three specific data points within 30 days: CMS final payment notice (expected early April), weekly MA enrollment flow reports (through Mar 31), and Q1 earnings commentary (UNH, HUM, CVS in Apr–May). If CMS change ≤2% and net MA flows favor large players by >1% share, add incremental 1–2% exposure to UNH/HUM.